Abstract:Highlights • Development of first in class on-demand milling platform • Accelerated process development for particle engineering at DS/DP interface. • PATs leveraged to deduce crystallization mechanisms. • Successful manipulation of crystal morphology and size to improve physical properties. Automation plays a vital role in reducing development time in the pharmaceutical industry, both for drug substance (DS) and drug product (DP). Many aspects of crystallization development (solubility, kinetics, solid form characterization, concentration) have been positively impacted by automation; both in hardware and data processing, in the last two decades. However, wet milling, a critical unit operation used to manipulate particle properties in a crystallization process, has been non-conducive for automation. This study discusses efforts towards automation of wet milling, coupled with off-the-shelf automation tools for faster execution of physical property design workflows. The hardware and software configuration used, along with challenges and prospects to achieve milling automation are discussed. Lovastatin was used as a model compound to demonstrate the capabilities of the automated platform to achieve morphology and size manipulation. Five different batches of lovastatin were produced using different combinations of milling and thermal cycling. Milling followed by thermal cycling led to formation of rougher, fused particles with a lower aspect ratio compared to those produced by thermal cycling followed by milling. In-situ particle video microscopy was used to decipher that the initial increase in particle size during thermal cycling was driven by a fusion of primary particles followed by growth. Key material property descriptors such as bulk/tap density, flow function coefficient, surface area, and particle size by laser diffraction were collected using traditional means while particle size, aspect ratio and smoothness were also measured using image analysis. Lastly, principal component analysis (dimensionality reduction) was performed to determine the key property relationships impacting flowability. It was found that fines as measured by d10 (10 th percentile of the volumetric size distribution) and Hausner ratio had a high positive and negative correlation, respectively with flowability. The on demand milling platform combined with data rich trials using PAT is estimated to accelerate process development for particle engineering and reduce the drug substance delivery time to drug product team.

Integrated Continuous Process Design for Crystallisation, Spherical Agglomeration, and Filtration of Lovastatin

Development of Continuous Filtration in a Novel Continuous Filtration Carousel Integrated with Continuous Crystallization

Enabling precision manufacturing of active pharmaceutical ingredients: workflow for seeded cooling continuous crystallisations

Developing the biofacility of the future based on continuous processing and single-use technology

Establishment of a semi-continuous nano-production line using the Microfluidizer® technology for the fabrication of lipid-based nanoparticles part 1: Screening of critical parameters and design of experiment optimization studies

Automated Continuous Crystallization Platform with Real-Time Particle Size Analysis via Laser Diffraction

Small-Scale Continuous Drug Product Manufacturing using Dropwise Additive Manufacturing and Three Phase Settling for Integration with Upstream Drug Substance Production

Computational fluid dynamics simulation of a jet crystallizer for continuous crystallization of lovastatin

Integrated Filtration and Washing Modeling: Optimization of Impurity Rejection for Filtration and Washing of Active Pharmaceutical Ingredients

Compact Crystallization, Filtration, and Drying for the Production of Active Pharmaceutical Ingredients

Use of automation, dynamic image analysis, and process analytical technologies to enable data rich particle engineering efforts at the Drug Substance / Drug Product interface: A case study using Lovastatin

A Comprehensive Workflow towards More Equant‐Shaped Crystals of Active Pharmaceutical Ingredients

End-to-end continuous manufacturing of conventional compressed tablets: From flow synthesis to tableting through integrated crystallization and filtration

Automated Self-Optimization of Continuous Crystallization of Nirmatrelvir API

Tailoring the crystal size distribution of an active pharmaceutical ingredient by continuous antisolvent crystallization in a planar oscillatory flow crystallizer

Continuous Manufacturing of Cocrystals Using 3D-Printed Microfluidic Chips Coupled with Spray Coating

Continuous Embedded Droplet Printing in Yield‐Stress Fluids for Pharmaceutical Drug Particle Synthesis

Ultrasound-assisted Continuous Crystallization of Metastable Polymorphic pharmaceutical in a Slug-flow Tubular Crystallizer

Modeling of Continuous Slug Flow Cooling Crystallization towards Pharmaceutical Applications

On-demand Continuous-Flow Production of Pharmaceuticals in a Compact, Reconfigurable System.

Strategy for Fast Decision on Material System Suitability for Continuous Crystallization Inside a Slug Flow Crystallizer